Back to search results

Preventing HIV and Infections in People Who Use Opioids

This study, called Prescribe to Prevent HIV (P2PH), aims to help addiction clinics offer two important ways to prevent HIV and other infections for people who use opioids: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Many people who inject drugs don't have access to these tools, leading to a rise in infections. This study will work with clinics to create and test new ways to make sure these services are available. The goal is to see if clinics can successfully adopt and continue to use these strategies to help patients. You could be eligible if you are an adult with a history of injecting drugs in the past year. The study is looking to enroll 536 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific strategy bundle. The study plans to enroll 536 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at how well the strategies are adopted at 6 months and maintained at 12 months after they are put in place.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07073924

Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support

Not Yet Recruiting
NAAges 18+InterventionalHealth services
University of Pittsburgh
~536 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Implementation strategy bundle

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Implementation Outcomes: Site Level Adoption
Measured over 6 months post implementation
+2 more outcomes measured

Conditions

People Who Use Opioids/People With Opioid Use Disorder (OUD)

Explore related trials

Opioid Use DisorderSubstance-Related Disorder

Where it's being run

4 sites across 1 states
Pennsylvania4

Study leadership

  • Raagini Jawa, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Raagini Jawa, MD, MPH
[email protected]
(412) 232-6275
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients with history of active injection drug use in the past 1 year from the 4 COEs
Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs

Exclusion

Ages \<18
If history of injection drug use \>1 year
Non-English speaking
Pending or legal action that could prohibit or interfere with participation (Ie. incarceration)
Residence or discharge to a treatment facility that bans the possession of drug checking supplies
Acute, severe psychiatric condition in need of immediate treatment.
Individuals not affiliated with the 4 COEs.
Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses).
Students, trainees, or individuals not credentialed in the eligible roles.
Those on extended leave or not actively working during the study period.

What this trial measures

  • Implementation Outcomes: Site Level Adoption6 months post implementation

    This is defined as the proportion of clinicians who prescribed injection equipment and/or PrEP per site, assessed at 6 months post-implementation, respectively using electronic health record data.

  • Implementation Outcomes: Site-level maintenance12 months post implementation

    This is defined as the proportion of clinicians who prescribed injection equipment and/or PrEP per site, assessed at 12 months post-implementation respectively using electronic health record data.

  • Implementation Outcomes: Acceptability of the strategy bundle6 months post implementation

    Acceptability of the implementation strategy bundle will be assessed via post-implementation surveys of participating clinical partners (N=60-80) using a reliable 4-item survey from Weiner et al., where scores ≥16 indicate "acceptable" if 80% of participants agree.